The carefully controlled roll-out of transcatheter aortic valve replacement in the U.S. appears to be working as intended so far. The first report of national postmarket TAVR registry data shows the procedural success rates and early complication rates are no worse than they were in the randomized trials or registries in other countries.
The first results from the American College of Cardiology (ACC) and Society of Thoracic Surgeons (STS) TVT Registry